Zacks Investment Research upgraded shares of FibroGen (NASDAQ:FGEN) from a hold rating to a buy rating in a report published on Tuesday. They currently have $52.00 price objective on the biopharmaceutical company’s stock.

According to Zacks, “FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California. “

Several other research firms have also recently weighed in on FGEN. Leerink Swann set a $82.00 price target on shares of FibroGen and gave the stock a buy rating in a report on Tuesday, September 11th. ValuEngine cut shares of FibroGen from a strong-buy rating to a buy rating in a research note on Monday, September 17th. BidaskClub cut shares of FibroGen from a strong-buy rating to a buy rating in a research note on Tuesday, October 9th. TheStreet cut shares of FibroGen from a c- rating to a d+ rating in a research note on Wednesday, November 21st. Finally, Mizuho reiterated a buy rating and issued a $74.00 target price on shares of FibroGen in a research note on Monday, December 17th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of Buy and an average price target of $70.25.

FibroGen stock traded down $0.43 during midday trading on Tuesday, hitting $47.48. 5,449 shares of the stock were exchanged, compared to its average volume of 778,840. FibroGen has a 52-week low of $37.27 and a 52-week high of $68.55. The stock has a market cap of $4.08 billion, a PE ratio of -27.57 and a beta of 1.67. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.76 and a current ratio of 6.76.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.15). FibroGen had a negative return on equity of 24.59% and a negative net margin of 87.84%. The firm had revenue of $29.00 million for the quarter, compared to analysts’ expectations of $36.48 million. The business’s revenue was down 28.6% compared to the same quarter last year. As a group, analysts predict that FibroGen will post -1.55 EPS for the current fiscal year.

In other news, Director James A. Schoeneck sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, January 7th. The shares were sold at an average price of $45.90, for a total value of $91,800.00. Following the sale, the director now owns 29,700 shares of the company’s stock, valued at $1,363,230. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Thomas B. Neff sold 18,900 shares of the business’s stock in a transaction that occurred on Thursday, October 18th. The shares were sold at an average price of $54.52, for a total transaction of $1,030,428.00. Following the completion of the sale, the chief executive officer now directly owns 2,710,412 shares in the company, valued at approximately $147,771,662.24. The disclosure for this sale can be found here. In the last three months, insiders sold 205,924 shares of company stock worth $9,021,309. Insiders own 8.96% of the company’s stock.

Several large investors have recently modified their holdings of FGEN. FMR LLC increased its holdings in shares of FibroGen by 22.9% in the 2nd quarter. FMR LLC now owns 8,404,819 shares of the biopharmaceutical company’s stock worth $526,142,000 after buying an additional 1,566,040 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of FibroGen by 37.8% in the 3rd quarter. First Trust Advisors LP now owns 1,652,213 shares of the biopharmaceutical company’s stock worth $100,372,000 after buying an additional 453,288 shares during the last quarter. PointState Capital LP increased its holdings in shares of FibroGen by 92.0% in the 2nd quarter. PointState Capital LP now owns 810,200 shares of the biopharmaceutical company’s stock worth $50,719,000 after buying an additional 388,300 shares during the last quarter. BlackRock Inc. increased its holdings in shares of FibroGen by 4.6% in the 2nd quarter. BlackRock Inc. now owns 6,182,657 shares of the biopharmaceutical company’s stock worth $387,037,000 after buying an additional 271,981 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its stake in shares of FibroGen by 118.4% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 410,900 shares of the biopharmaceutical company’s stock valued at $24,962,000 after purchasing an additional 222,800 shares in the last quarter. 64.86% of the stock is currently owned by hedge funds and other institutional investors.

About FibroGen

FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.

Further Reading: What Are Treasury Bonds?

Get a free copy of the Zacks research report on FibroGen (FGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.